News & Updates

Patients with type 2 diabetes mellitus (T2DM) taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) are less likely to be prescribed antigout or antihyperuricaemic drugs, a recent study has found.

In patients with type 2 diabetes (T2D) with chronic kidney disease (CKD), once-weekly dosage with dulaglutide achieves adequate glycaemic control along with a reduced decline in estimated glomerular filtration rate (eGFR), reports a recent study.

Communicating the risks of type 2 diabetes needs to be done in an emotionally impactful way while also having an interpersonal appeal, according to a recent Singapore study. To improve the uptake of healthy lifestyle practices, shifting from a long-term view of the disease to more short-term, observable benefits may be valuable.

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

A recent study attempting to understand the pathogenesis of Cushing’s disease (CD) suggests the potential of achaete-scute complex homolog 1 (ASCL1), a pioneer transcription factor, as a therapeutic target for the treatment of CD.

High levels of high-density lipoprotein (HDL) cholesterol appear to correlate with better changes in memory and executive function in older adults with diabetes mellitus, according to a recent China study.

People with worse overall psychological wellbeing are at significantly higher risk of developing type 2 diabetes (T2D) in a dose‒response manner irrespective of their genetic predisposition, suggest the results of a recent study.